Takeda
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor
The agency approved Foundation Medicine's tissue-based, next-generation sequencing test to identify patients with ALK-positive NSCLC eligible for Alunbrig.
Bristol Myers Squibb, LabCorp, NeoGenomics, Others Join Consortium to Improve COVID-19 Testing
The consortium seeks to accelerate research and clinical diagnostic applications through collaboration with the ultimate goal of improving COVID-19 testing.
Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Takeda's Alunbrig Gets First-Line FDA Approval With Abbott CDx in ALK-Positive Lung Cancer
The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.